Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
cSCC is one of the most common cancers in the U.S. and globally
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
Subscribe To Our Newsletter & Stay Updated